Flurazepam

CHEMBL968 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
387.9 g/mol
LogP
3.0
Phase
4

A benzodiazepine medication prescribed for the short-term treatment of insomnia, helping patients fall asleep faster and stay asleep longer by enhancing the activity of GABA, a calming brain chemical. Due to its long half-life, it may cause next-day drowsiness and impair coordination. It carries a risk of dependence and is not recommended for long-term use.

น้ำหนักโมเลกุล

387.9000 g/mol

LogP

3.00

TPSA

35.90 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21

InChI

InChI=1S/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3

Molecular Formula

C21H23ClFN3O

HBD / HBA

- / 4

พันธะที่หมุนได้

6

อะตอมหนัก

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A benzodiazepine medication prescribed for the short-term treatment of insomnia, helping patients fall asleep faster and stay asleep longer by enhancing the activity of GABA, a calming brain chemical. Due to its long half-life, it may cause next-day drowsiness and impair coordination. It carries a risk of dependence and is not recommended for long-term use.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Flurazepam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL968. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3393. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.